Cart
sales@molnova.com
BGC201531
CAS No. 1186532-61-5
BGC201531( GTPL3380 | AP-1531 | BGC-20-1531 )
Catalog No. M23357 CAS No. 1186532-61-5
BGC201531 is a EP4 antagonist for the treatment of acute migraine.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 272 | In Stock |
|
| 10MG | 408 | In Stock |
|
| 25MG | 735 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBGC201531
-
NoteResearch use only, not for human use.
-
Brief DescriptionBGC201531 is a EP4 antagonist for the treatment of acute migraine.
-
DescriptionBGC201531 is a EP4 antagonist for the treatment of acute migraine.
-
In Vitro——
-
In Vivo——
-
SynonymsGTPL3380 | AP-1531 | BGC-20-1531
-
PathwayGPCR/G Protein
-
TargetProstaglandin Receptor
-
RecptorEP4
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1186532-61-5
-
Formula Weight496.58
-
Molecular FormulaC26H28N2O6S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC1=CC=CC=C1S(=O)(=O)[N-]C(=O)C2=CC(=C(O2)C)COC3=CC=C(C=C3)C4=NC=C(C=C4)OC.[Na+]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Czigler A , Toth L , Szarka N , et al. Prostaglandin E2, a postulated mediator of neurovascular coupling, at low concentrations dilates whereas at higher concentrations constricts human cerebral parenchymal arterioles[J]. Prostaglandins & other lipid mediators, 2019, 146:106389.
molnova catalog
related products
-
EP4 receptor antagon...
EP4 receptor antagonist 1 inhibits human and mouse EP4 receptor with IC50s of 6.1 nM and 16.2 nM, respectively.
-
Terutroban
Terutroban (S-18886) is a potent, selective antagonist of the thromboxane receptor (Prostanoid TP receptor) that blocks thromboxane induced platelet aggregation and vasoconstriction.
-
Bimatoprost
Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension.
